

Payments to Healthcare Professionals

Collaboration between the pharmaceutical industry and Healthcare Professionals (HCPs) or Healthcare Organizations (HCOs) benefits patients. It is a relationship that has delivered numerous breakthrough medicines and changed the way many diseases impact patients' lives. Our work together includes a range of activities from clinical research to sharing best clinical practice. As an industry we make payments or 'transfers of value' to Healthcare Professionals and Organizations to compensate them for the time spent working with us.

Bringing greater transparency to this already well-regulated relationship builds understanding of this collaboration and addresses public concerns about interactions between the medical community and the pharmaceutical industry. We believe that openly communicating payments helps foster trust with patients, Healthcare Professionals, government officials and the public, and supports our overall commitment to data transparency and high ethical business standards. Novartis has long been dedicated to improving [clinical trial data transparency](#) and discloses [relationships with patient organizations](#).

In several countries, we publish payments to Healthcare Professionals and Organizations in line with local laws or regulations.

About our Reporting Practices

Europe

Across Europe, Novartis discloses annually payments and other transfers of value in line with the [European Federation of Pharmaceutical Industries and Associations \(EFPIA\) Disclosure Code](#) and its local transpositions. [The EFPIA Disclosure Code 2024 Self-Certification Letter \(PDF 0.4 MB\)](#) signed by Patrick Horber, Novartis President, International, confirms the application of the [principles of the EFPIA Disclosure Code](#). The letter from previous year is available [here \(PDF 0.1 MB\)](#).

Novartis also complies with the Medicines for Europe (European Generic and Biosimilar Medicines Association) Transparency Rules and Requirements, which defines disclosure rules for the generic, biosimilar and value added medicines industry.

Following the spin-off of Sandoz from Novartis in November 2023, Novartis will still be responsible for publishing the 2023 Transparency of Value (ToV) for Sandoz, covering 2023 ToV reporting. However, from 2025 onwards, only Novartis's ToV will be published. This means that any transparency and disclosure related to Sandoz for 2024 will not be included in Novartis's publications and starting from 2025, Sandoz will handle its own reporting separately.

United States

Novartis Pharmaceuticals Corporation (NPC) is required each year to submit data to the [Centers for Medicare and Medicaid Services \(CMS\) Open Payments program](#) (commonly known as [the Sunshine Act](#)) as an applicable manufacturer. CMS collects information about certain payments and other transfers of value from applicable manufacturers and group purchasing organizations (GPOs) to physicians and teaching hospitals. Open Payments is the federally run transparency program that collects information about these financial

relationships and makes it available to the public annually through the [CMS Open Payments website](#).

[Read more about our Payments to Healthcare Professionals in the United States.](#)

Rest of the world

In addition to the EFPIA countries and the United States, we publicly disclose payments and transfers of value in Australia, Brazil, Colombia, Canada, Israel, Japan and New Zealand. In Chile, Indonesia, Pakistan, Philippines and Saudi Arabia, transfers of value are reported to the government. In South Korea, transfers of value are gathered and shared with the Ministry of Health upon request.

All Disclosure Reports

Australia

Disclosure Report

[English](#)

Austria

Disclosure Report

[Novartis](#)

[Sandoz](#)

Belgium

Disclosure Report

Novartis

[French](#)

[Dutch](#)

Sandoz

[French](#)

[Dutch](#)

Bosnia and Herzegovina

Below is the disclosure information for Bosnia and Herzegovina in English as per EFPIA regulations. In case of questions please [contact us](#).

2023

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

2022

Novartis

[Disclosure Report \(PDF 0.4 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

Sandoz

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

2021

Novartis

[Disclosure Report \(PDF 0.6 MB\)](#)

[Methodological Note \(PDF 0.7 MB\)](#)

Sandoz

[Disclosure Report \(PDF 0.5 MB\)](#)

[Methodological Note \(PDF 0.8 MB\)](#)

Brazil

Disclosure Report

[Portuguese](#)

Bulgaria

Disclosure Report

[Novartis](#)

[Sandoz](#)

Canada

Disclosure Report

Novartis

[English](#)

[French](#)

Sandoz

[English](#)

[French](#)

Colombia

Disclosure Report

[Spanish](#)

Croatia

Sukladno pravilima EFPIA udruženja niže su navedeni podaci na hrvatskom jeziku za objavu za Hrvatsku. U slučaju pitanja molimo Vas da nas [kontaktirate](#).

2023

Novartis

[Disclosure Report \(PDF 1 MB\)](#)

[Methodological Note \(PDF 0.2 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

2022

Novartis

[Disclosure Report – EUR \(PDF 0.3 MB\)](#)

[Disclosure Report – HRK \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

Sandoz

[Disclosure Report – EUR \(PDF 0.2 MB\)](#)

[Disclosure Report – HRK \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

2021

Novartis

[Disclosure Report \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.6 MB\)](#)

Sandoz

[Disclosure Report \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.6 MB\)](#)

Cyprus

Below is the disclosure information for Cyprus in English as per EFPIA regulations. In case of questions please [contact us](#).

2023

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

2022

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

Sandoz

[Methodological Note \(PDF 0.5 MB\)](#)

2021

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.6 MB\)](#)

Sandoz

[Methodological Note \(PDF 0.5 MB\)](#)

Czech Republic

Disclosure Report

[Novartis](#)

[Sandoz](#)

Denmark

Disclosure Report

[Novartis](#)

Sandoz

Estonia

Disclosure Report

Estonian

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

Finland

Disclosure Report

Novartis

Sandoz

France

Disclosure Report

French

Germany

Disclosure Report

Novartis

Sandoz

Greece

Disclosure Report

Greek

Hungary

Disclosure Report

Novartis

Sandoz

Iceland

Disclosure Report

Novartis

Sandoz

Ireland

Disclosure Report

English

Israel

Disclosure Report

Hebrew

Italy

Disclosure Report

Italian

For 2023 Sandoz Disclosure reports, please refer to - [Codice sulla Trasparenza | Sandoz Italia](#)

Japan

Disclosure Report

Novartis

Sandoz

Latvia

Disclosure Report

Latvian

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

Lithuania

Disclosure Report

Lithuanian

Luxembourg

Below is the disclosure information for Luxembourg in English as per EFPIA regulations. In case of questions please [contact us](#).

2023

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

2022

Novartis

[Disclosure Report \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

Sandoz

[Methodological Note \(PDF 0.2 MB\)](#)

2021

Novartis

[Disclosure Report \(PDF 0.1 MB\)](#)

[Methodological Note \(PDF 0.6 MB\)](#)

Sandoz

[Methodological Note \(PDF 0.5 MB\)](#)

Malta

Below is the disclosure information for Malta in English as per EFPIA regulations. In case of questions please [contact us](#).

2023

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

2022

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

Sandoz

[Methodological Note \(PDF 0.5 MB\)](#)

2021

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.6 MB\)](#)

Sandoz

[Methodological Note \(PDF 0.5 MB\)](#)

Netherlands

Disclosure Report

[Novartis](#)

[Sandoz](#)

New Zealand

Disclosure Report

[English](#)

North Macedonia

Below is the disclosure information for North Macedonia in English as per EFPIA regulations. In case of questions please [contact us](#).

2023

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

2022

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

Sandoz

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

2021

Novartis

[Disclosure Report \(PDF 0.2 MB\)](#)

[Methodological Note \(PDF 0.7 MB\)](#)

Sandoz

[Disclosure Report \(PDF 0.1 MB\)](#)

[Methodological Note \(PDF 0.32 MB\)](#)

Norway

Disclosure Report

[Novartis](#)

[Sandoz](#)

Philippines

Disclosure Report

[English](#)

Poland

Disclosure Report

[Polish](#)

Portugal

Disclosure Report

[Portuguese](#)

Romania

Disclosure Report

[Novartis](#)

[Sandoz](#)

Russia

Disclosure Report

[Novartis](#)

[Sandoz](#)

Serbia

U prilogu se nalaze informacije koje će biti objavljene za Srbiju, na srpskom jeziku, po regulativi EFPIE. U slučaju bilo kakvih pitanja budite slobodni da nas [kontaktirate](#).

2023

Novartis

[Disclosure Report \(PDF 0.5 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

Sandoz

[Disclosure Report \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.2 MB\)](#)

2022

Novartis

[Disclosure Report \(PDF 0.5 MB\)](#)

[Methodological Note \(PDF 0.4 MB\)](#)

Sandoz

[Disclosure Report \(PDF 0.6 MB\)](#)

[Methodological Note \(PDF 0.5 MB\)](#)

2021

Novartis

[Disclosure Report \(PDF 0.7 MB\)](#)

[Methodological Note \(PDF 0.8 MB\)](#)

Sandoz

[Disclosure Report \(PDF 0.9 MB\)](#)

[Methodological Note \(PDF 0.9 MB\)](#)

Slovakia

Disclosure Report

[Novartis](#)

[Sandoz](#)

Slovenia

Spodaj so glede na zahteve EFPIA v slovenskem jeziku objavljeni podatki o prenosih sredstev. V primeru morebitnih vprašanj nas prosimo [kontaktirajte](#).

2023

Novartis

[Disclosure Report \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

For 2023 Sandoz Disclosure reports, please refer to [Payments to Healthcare Professionals | Sandoz](#)

2022

Novartis

[Disclosure Report \(PDF 0.3 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

Sandoz

[Disclosure Report \(PDF 0.4 MB\)](#)

[Methodological Note \(PDF 0.3 MB\)](#)

2021

Novartis

[Disclosure Report \(PDF 0.4 MB\)](#)

[Methodological Note \(PDF 0.4 MB\)](#)

Sandoz

[Disclosure Report \(PDF 0.6 MB\)](#)

[Methodological Note \(PDF 0.4 MB\)](#)

South Korea

Disclosure Report

[Novartis](#)

Spain

Disclosure Report

[Novartis](#)

[Sandoz](#)

Sweden

Disclosure Report

[Novartis](#)

[Sandoz](#)

Switzerland

Disclosure Report

Novartis

German

French

Sandoz

German

French

Turkey

Disclosure Report

Novartis

Sandoz

UK

Disclosure Report

Novartis

Sandoz

Ukraine

Disclosure Report

Ukrainian

United States

Disclosure Report

Novartis

Sandoz

Source URL: <https://prod1.novartis.com/investors/reporting-and-transparency-hub/payments-healthcare-professionals>

List of links present in page

1. <https://prod1.novartis.com/investors/reporting-and-transparency-hub/payments-healthcare-professionals>
2. <https://prod1.novartis.com/clinicaltrials>
3. <https://prod1.novartis.com/investors/reporting-and-transparency-hub/patient-organization-funding>
4. <https://www.efpia.eu/relationships-code/the-efpia-code/>
5. https://prod1.novartis.com/sites/novartis_com/files/efpia-self-certification-scheme-2024.pdf
6. <https://www.efpia.eu/relationships-code/healthcare-professionals-hcps/>
7. https://prod1.novartis.com/sites/novartis_com/files/efpia-self-certification-scheme-2023.pdf
8. <https://www.cms.gov/>

9. <https://www.novartis.us/corporate-responsibility/payments-hcps-hcos>
10. <https://openpaymentsdata.cms.gov/search>
11. <https://www.novartis.us/corporate-responsibility/payments-hcps-hcos>
12. <https://www.novartis.com.au/about-us/corporate-responsibility/corporate-responsibility-australia/financial-transparency>
13. <https://www.novartis.at/ueber-uns/verantwortung/transparenz-ueber-zahlungen-angehoerige-der-fachkreise>
14. <https://www.sandoz.at/ueber-uns/verantwortung/transparenz-ueber-zahlungen-angehoerige-der-fachkreise>
15. <https://www.novartis.be/fr/transparence-des-paiements-aux-professionnels-de-sante>
16. <https://www.novartis.be/nl/transparantie-van-betalingen-aan-gezondheidszorgverleners>
17. <https://www.sandoz.be/fr/transparence-des-paiements-aux-professionnels-de-sante>
18. <https://www.sandoz.be/nl/transparantie-van-betalingen-aan-gezondheidszorgverleners>
19. <https://www.novartis.com/our-company/contact-us/office-locations>
20. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-bosnia-2023.pdf
21. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-novartis-bosnia-2023.pdf
22. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
23. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-bosnia-2022.pdf
24. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-novartis-bosnia-2022.pdf
25. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-bosnia-2022.pdf
26. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-sandoz-bosnia-2022.pdf
27. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-bosnia-2021.pdf
28. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-novartis-bosnia-2021.pdf
29. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-bosniaherzegovina-2021.pdf
30. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-sandoz-bosniaherzegovina-2021.pdf
31. <https://declarasus.saude.mg.gov.br/>
32. <https://www.novartis.com/bg-bg/esg/transparency>
33. <https://www.sandoz.bg/za-nas/korporativna-otgovornost/prozrachnost>
34. <https://www.novartis.ca/about-us/corporate-responsibility/transparency-voluntary-disclosure-payments-healthcare>
35. <https://www.novartis.ca/fr/about-us/corporate-responsibility/la-transparence-divulgence-volontaire-des-paiements-aux>
36. <https://www.sandoz.ca/transparency-initiative>
37. <https://www.sandoz.ca/fr/initiative-transparence>
38. <https://www.novartis.com/co-es/sobre-novartis/etica-e-integridad>
39. [https://prod1.novartis.com/about/locations?
field_location_business_unit_target_id=All&field_location_country_target_id=4586](https://prod1.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4586)
40. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-croatia-2023.pdf
41. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-novartis-croatia-2023.pdf
42. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
43. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-croatia-2022-eur.pdf
44. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-croatia-2022-hrk.pdf
45. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-novartis-croatia-2022.pdf
46. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-croatia-2022-eur.pdf
47. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-croatia-2022-hrk.pdf
48. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-sandoz-croatia-2022.pdf
49. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-croatia-2021.pdf
50. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-novartis-croatia-2021.pdf
51. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-croatia-2021.pdf
52. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-croatia-imsz-2021.pdf
53. [https://prod1.novartis.com/about/locations?
field_location_business_unit_target_id=All&field_location_country_target_id=4501](https://prod1.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4501)
54. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-cyprus-2023.pdf
55. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-novartis-cyprus-2023.pdf
56. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
57. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-cyprus-2022.pdf
58. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-cyprus-novartis-2022.pdf

59. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-cyprus-sandoz-2022.pdf
60. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-cyprus-2021-v2.pdf
61. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-cyprus-novartis-2021.pdf
62. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-cyprus-sandoz-2021.pdf
63. <https://www.novartis.cz/cs/transparentni-spoluprace-zverejneni>
64. <https://www.sandoz.cz/doing-business-responsibly>
65. <https://www.novartis.dk/om-novartis/hvem-samarbejder-vi-med#ui-id-1=0>
66. <https://www.sandoz.dk/transparency-disclosure-efpia>
67. <https://www.novartis.ee/koostoeoe-tervishoiutoeoetajatega>
68. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
69. <https://www.novartis.fi/novartis-yrityksena/yritysvastuu/yhteistyo>
70. <https://www.sandoz.fi/transparency-disclosure-efpia>
71. <https://www.novartis.fr/propos-de-novartis/notre-activite/transparence-des-relations>
72. <https://www.novartis.de/transparenzkodex>
73. <https://www.sandoz.de/ueber-uns/verantwortungsbewusste-geschaeftsfuehrung/transparenz-von-leistungen-fachkreisangehoerige>
74. <https://www.novartis.gr/sustainable-development/business-ethic/disclosure-code>
75. <https://www.novartis.com/hu-hu/egeszsegugyi-szakemberek/atlatthatosag>
76. <https://www.sandoz.hu/rolunk/felelos-uzletvitel>
77. <https://frumtok.is/sidareglur/>
78. <https://www.sandoz.dk/transparency-disclosure-efpia>
79. <https://www.novartis.ie/ethics-and-compliance-transparency>
80. https://www.health.gov.il/Subjects/Finance/Pages/donation_reports.aspx
81. <https://www.novartis.it/su-di-noi/responsabilita-sociale/etica-persone-ambiente/codice-sulla-trasparenza>
82. <https://www.sandoz.it/su-di-noi/condotta-responsabile-del-business/codice-sulla-trasparenza/>
83. <https://www.novartis.com/jp-ja/esg/transparency>
84. <https://www.sandoz.jp/about-us>
85. <https://www.novartis.com/lv-lv/veselibas-aprupes-specialisti/sadarbiba-ar-veselibas-aprupes-specialistiem>
86. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
87. <https://www.novartis.com/lt-lt/sveikatos-prieziuros-specialistai/bendradarbiavimas-su-sveikatos-prieziuros-specialistais>
88. [https://prod1.novartis.com/about/locations?
field_location_business_unit_target_id=All&field_location_country_target_id=4681](https://prod1.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4681)
89. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-luxembourg-2023.pdf
90. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-novartis-luxembourg-2023.pdf
91. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
92. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-luxembourg-2022.pdf
93. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-luxembourg-novartis-2022.pdf
94. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-luxembourg-sandoz-2022.pdf
95. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-luxembourg-2021.pdf
96. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-luxembourg-novartis-2021.pdf
97. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-luxembourg-sandoz-2021.pdf
98. [https://prod1.novartis.com/about/locations?
field_location_business_unit_target_id=All&field_location_country_target_id=4706](https://prod1.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4706)
99. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-malta-2023.pdf
100. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-novartis-malta-2023.pdf
101. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
102. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-malta-2022.pdf
103. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-malta-novartis-2022.pdf
104. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-malta-sandoz-2022.pdf
105. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-malta-2021.pdf
106. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-malta-novartis-2021.pdf
107. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-malta-sandoz-2021.pdf
108. <https://www.novartis.nl/transparantie-nederland>
109. <https://www.sandoz.nl/over-ons/verantwoord-zakendoen>
110. <https://www.novartis.com.au/about-us/corporate-responsibility/corporate-responsibility-australia-new-zealand/financial-transparency-for-new-zealand>
111. [https://www.novartis.com/about/locations?
field_location_business_unit_target_id=All&field_location_country_target_id=4701](https://www.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4701)

112. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-north-macedonia-2023.pdf
113. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-novartis-north-macedonia-2023.pdf
114. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
115. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-north-macedonia-2022.pdf
116. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-novartis-northmacedonia-2022.pdf
117. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-northmacedonia-2022.pdf
118. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-sandoz-north-macedonia-2022.pdf
119. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-macedonia-2021.pdf
120. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-novartis-macedonia-2021.pdf
121. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-north-macedonia-2021.pdf
122. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-sandoz-north-macedonia-2021.pdf
123. <https://www.novartis.com/no-no/om-oss/pengeoverforing-til-helsetjenesten>
124. <https://www.sandoz.no/transparency-disclosure-efpia>
125. <https://www.novartis.com/ph-en/esg/financial-transparency-philippines>
126. <https://www.novartis.pl/wspolpraca-z-przedstawicielami-zawodow-medycznych-oraz-organizacjami-ochrony-zdrowia#ui-id-1=0>
127. <https://www.novartis.pt/transferencias-de-valor-profissionais-e-organizacoes-de-saude>
128. <https://www.novartis.com.ro/contributia-noastra/transparenta>
129. <https://www.sandoz.ro/despre-noi/etica-si-conformitate>
130. <https://www.novartis.ru/about-us/corporate-responsibility/general-disclosure>
131. <https://www.sandoz.ru/o-kompanii/otvetstvennoe-vedenie-biznesa/general-disclosure>
132. [https://prod1.novartis.com/about/locations?
field_location_business_unit_target_id=All&field_location_country_target_id=4801](https://prod1.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4801)
133. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-serbia-2023.pdf
134. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-novartis-serbia-2023.pdf
135. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-serbia-2023.pdf
136. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-sandoz-serbia-2023.pdf
137. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-serbia-2022.pdf
138. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-novartis-serbia-2022.pdf
139. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-serbia-2022.pdf
140. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-sandoz-serbia-2022.pdf
141. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-serbia-2021.pdf
142. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-novartis-serbia-2021.pdf
143. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-serbia-2021.pdf
144. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-sandoz-serbia-2021.pdf
145. <https://www.novartis.sk/o-nas/spolocenska-zodpovednost/transparentnost-v-platbach-zdravotnickym-pracovnikom>
146. <https://www.sandoz.sk/o-nas/transparentna-spolupraca>
147. [https://prod1.novartis.com/about/locations?
field_location_business_unit_target_id=All&field_location_country_target_id=4826](https://prod1.novartis.com/about/locations?field_location_business_unit_target_id=All&field_location_country_target_id=4826)
148. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-slovenia-2023.pdf
149. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-novartis-slovenia-2023.pdf
150. <https://www.sandoz.com/transparency/payments-healthcare-professionals/>
151. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-slovenia-2022.pdf
152. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-novartis-slovenia-2022.pdf
153. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-slovenia-2022.pdf
154. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-sandoz-slovenia-2022.pdf
155. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-novartis-slovenia-2021.pdf
156. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-novartis-slovenia-2021.pdf
157. https://prod1.novartis.com/sites/novartis_com/files/payment-disclosure-sandoz-slovenia-2021.pdf
158. https://prod1.novartis.com/sites/novartis_com/files/methodological-note-novartis-slovenia-2021.pdf
159. <https://www.novartis.com/kr-ko/esg/corporate-responsibility/doing-business-responsibility>
160. <https://www.novartis.es/sobre-novartis/responsabilidad-social/practica-empresarial->

responsable/transparencia-en-las

161. <https://www.sandozfarma.es/sobre-sandoz/responsabilidad-social-corporativa/practica-empresarial-responsable/transferencias-de>
162. <https://www.novartis.se/om-novartis/vart-ansvar/transparent-samarbete>
163. <https://www.sandoz.se/transparency-disclosure-efpia>
164. <https://www.novartis.ch/offenlegung>
165. <https://www.novartis.com/ch-fr/societe-environnement/publication-des-transferts-de-valeurs>
166. <https://www.sandoz-pharmaceuticals.ch/de/ueber-uns/verantwortungsvolle-geschaeftsfuehrung/offenlegung-der-geldwerten-leistungen-fachpersonen>
167. <https://www.sandoz-pharmaceuticals.ch/fr/ueber-uns/verantwortungsvolle-geschaeftsfuehrung/publication-des-transferts-des-valeurs-aux>
168. <https://www.novartis.com.tr/hakkimizda/kurumsal-sorumluluk>
169. <https://www.sandoz.com.tr/hakkimizda/yapma-sorumlulugumuz>
170. <https://www.novartis.com/uk-en/esg/transparency/healthcare-professional-payment-transparency>
171. <https://www.sandoz.uk.com/about-us/transparency/>
172. <https://aprad.org.ua/tematichni-rozdili/rozkrittia-informatsiyi/>
173. <https://www.pharma.us.novartis.com/corporate-responsibility/physician-payments-sunshine-act>
174. <https://www.us.sandoz.com/about-us/doing-business-responsibly>